PROGNOSTIC SIGNIFICANCE OF SURFACTANT PROTEIN A, SURFACTANT PROTEIN D, CLARA CELL PROTEIN 16, Sioo PROTEIN, TREFOIL FACTOR 3, AND PROSTATIC SECRETORY PROTEIN 94 IN IDIOPATHIC PULMONARY FIBROSIS, SARCOIDOSIS, AND CHRONIC PULMONARY OBSTRUCTIVE DISEASE

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F16%3A00065787" target="_blank" >RIV/65269705:_____/16:00065787 - isvavai.cz</a>

Výsledek na webu

<a href="http://mattioli1885journals.com/index.php/sarcoidosis/article/view/4350" target="_blank" >http://mattioli1885journals.com/index.php/sarcoidosis/article/view/4350</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

PROGNOSTIC SIGNIFICANCE OF SURFACTANT PROTEIN A, SURFACTANT PROTEIN D, CLARA CELL PROTEIN 16, Sioo PROTEIN, TREFOIL FACTOR 3, AND PROSTATIC SECRETORY PROTEIN 94 IN IDIOPATHIC PULMONARY FIBROSIS, SARCOIDOSIS, AND CHRONIC PULMONARY OBSTRUCTIVE DISEASE

Popis výsledku v původním jazyce

Background: Identification of serum and bronchoalveolar lavage fluid (BALF) biomarkers may facilitate diagnosis and prognostication in various lung disorders. Objective: Serum and BALF levels of surfactant protein A (SP-A), surfactant protein D (SP-D), Clara cell protein 16 (CC16), SIOO protein, trefoil factor 3 (TFF3), and prostatic secretory protein 94 (PSP94) were evaluated in 94 consecutive patients (idiopathic pulmonary fibrosis (IFF; n=18), sarcoidosis (n=25), chronic obstructive pulmonary disease (COPD; n=51)), and in 155 healthy controls. Methods: Biomarkers were measured at diagnosis and compared with disease characteristics. Both uniparametric and multiparametric analyses were used. Results: Seven significant correlations were found: 1) BALF PSP94 level correlated with prognosis of sarcoidosis (P=0.035); 2) BALF SP-D level with pulmonary functions in IFF (P=0.032); 3) BALF SP-D and TFF3 with IFF mortality (P=0.049 and 0.017, respectively); 4) serum TFF3 level with COPD mortality (P=0.006,); 5) serum SP-A with pulmonary functions impairment in IFF (P=0.011); 6) serum SP-D level was associated with HRCT interstitial score in IPF (P=0.0346); and 7) serum SP-A was associated with staging of COPD according to spirometry (P<0.001). Moreover, our analysis showed that some biomarker levels differed significantly among the diseases: 1) BALF SP-D level differed between sarcoidosis and IPF; 2) serum SP-A level differed among IPF, sarcoidosis, COPD and was also different from healthy controls; 3) serum S100A6, S100A11 levels differed among IPF, sarcoidosis, COPD from healthy controls 4) serum SP-D, CC16, TFF-3 levels distinguished IPF patients from healthy controls; and 5) serum CC16, TFF3, PSP94 distinguished COPD patients from healthy controls. Our study shows that some of selected biomarkers should have prognostic value in the analysed lung disorders.

Název v anglickém jazyce

PROGNOSTIC SIGNIFICANCE OF SURFACTANT PROTEIN A, SURFACTANT PROTEIN D, CLARA CELL PROTEIN 16, Sioo PROTEIN, TREFOIL FACTOR 3, AND PROSTATIC SECRETORY PROTEIN 94 IN IDIOPATHIC PULMONARY FIBROSIS, SARCOIDOSIS, AND CHRONIC PULMONARY OBSTRUCTIVE DISEASE

Popis výsledku anglicky

Background: Identification of serum and bronchoalveolar lavage fluid (BALF) biomarkers may facilitate diagnosis and prognostication in various lung disorders. Objective: Serum and BALF levels of surfactant protein A (SP-A), surfactant protein D (SP-D), Clara cell protein 16 (CC16), SIOO protein, trefoil factor 3 (TFF3), and prostatic secretory protein 94 (PSP94) were evaluated in 94 consecutive patients (idiopathic pulmonary fibrosis (IFF; n=18), sarcoidosis (n=25), chronic obstructive pulmonary disease (COPD; n=51)), and in 155 healthy controls. Methods: Biomarkers were measured at diagnosis and compared with disease characteristics. Both uniparametric and multiparametric analyses were used. Results: Seven significant correlations were found: 1) BALF PSP94 level correlated with prognosis of sarcoidosis (P=0.035); 2) BALF SP-D level with pulmonary functions in IFF (P=0.032); 3) BALF SP-D and TFF3 with IFF mortality (P=0.049 and 0.017, respectively); 4) serum TFF3 level with COPD mortality (P=0.006,); 5) serum SP-A with pulmonary functions impairment in IFF (P=0.011); 6) serum SP-D level was associated with HRCT interstitial score in IPF (P=0.0346); and 7) serum SP-A was associated with staging of COPD according to spirometry (P<0.001). Moreover, our analysis showed that some biomarker levels differed significantly among the diseases: 1) BALF SP-D level differed between sarcoidosis and IPF; 2) serum SP-A level differed among IPF, sarcoidosis, COPD and was also different from healthy controls; 3) serum S100A6, S100A11 levels differed among IPF, sarcoidosis, COPD from healthy controls 4) serum SP-D, CC16, TFF-3 levels distinguished IPF patients from healthy controls; and 5) serum CC16, TFF3, PSP94 distinguished COPD patients from healthy controls. Our study shows that some of selected biomarkers should have prognostic value in the analysed lung disorders.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FC - Pneumologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Sarcoidosis vasculitis and diffuse lung diseases

ISSN

1124-0490

e-ISSN

—

Svazek periodika

33

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

11

Strana od-do

224-234

Kód UT WoS článku

000393274000005

EID výsledku v databázi Scopus

—